CD11a (LFA-1alpha) Monoclonal Antibody (M17/4), Super Bright™ 702, eBioscience™, Invitrogen™

Description

• Description: The M17/4 monoclonal antibody reacts with mouse CD11a, the 180 kDa integrin alpha L, also known as the lymphocyte function associated antigen-1 (LFA-1) alpha chain
• LFA-1, formed by non-covalent association of CD11a with CD18 (integrin beta 2), serves as an important adhesion molecule involved in lymphocyte and granulocyte function
• CD54 (ICAM-1), CD102 (ICAM-2), and CD50 (ICAM-3) are ligands for LFA-1
• CD11a is expressed by all leukocytes
• Applications Reported: This M17/4 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This M17/4 antibody has been tested by flow cytometric analysis of mouse bone marrow cells
• This may be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Super Bright 702 is a tandem dye that can be excited with the violet laser line (405 nm) and emits at 702 nm
• We recommend using a 710/50 bandpass filter
• Please make sure that your instrument is capable of detecting this fluorochrome
• When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product No
• CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin
• CD11a is implicated in activation of LFA-1 complex
• CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling
• CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation
• Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3
• CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions
• Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases
• For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity
• Two transcript variants encoding different isoforms of CD11a have been found
• Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.